The terminal complement inhibitor eculizumab reduces thrombosis in patients with paroxysmal nocturnal haemoglobinuria

被引：0
|
作者：
Hillmen, P.
Hill, A.
Muus, P.
Duhrsen, U.
Risitano, A. M.
Schubert, J.
Young, N. S.
Schrezenmeier, H.
Szer, J.
Brodsky, R. A.
Socie, G.
Rollins, S. A.
Rother, R. P.
Bell, L.
Luzzatto, L.
机构：
[1] Leeds Teaching Hosp NHS Trust, Dept Haematol, Leeds, W Yorkshire, England
[2] Radboud Univ Med Ctr, Nijmegen, Netherlands
[3] Univ Hosp, Essen, Germany
[4] Med Federico Univ 2, Naples, Italy
[5] Univ Saarland, Sch Med, D-6650 Homburg, Germany
[6] NHLBI, NIH, Bethesda, MD 20892 USA
[7] Inst Klin Transfus & Immunogenet, Helmholtzstr, Germany
[8] Royal Melbourne Hosp, Melbourne, Vic, Australia
[9] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[10] Hosp St Louis, INSERM, Paris, France
[11] Alex Pahrmaceut Inc, Cheshire, CT USA
[12] Ist Toscano Tumori, Florence, Italy
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2007年 / 137卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
102
引用
收藏
页码：34 / 34
页数：1
相关论文
共 50 条
  • [21] Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS Clinical Trial
    Kanakura, Yuzuru
    Ohyashiki, Kazuma
    Shichishima, Tsutomu
    Okamoto, Shinichiro
    Ando, Kiyoshi
    Ninomiya, Haruhiko
    Kawaguchi, Tatsuya
    Nakao, Shinji
    Nakakuma, Hideki
    Nishimura, Jun-ichi
    Kinoshita, Taroh
    Bedrosian, Camille L.
    Valentine, Marye Ellen
    Khursigara, Gus
    Ozawa, Keiya
    Omine, Mitsuhiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2011, 93 (01) : 36 - 46
  • [22] Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients
    Adhikari, Sugat
    Sapkota, Surendra
    Shrestha, Suraj
    Karki, Kshitiz
    Shrestha, Anjan
    ORPHANET JOURNAL OF RARE DISEASES, 2023, 18 (01)
  • [23] Eculizumab for paroxysmal nocturnal haemoglobinuria: catastrophic health expenditure in Nepalese patients
    Sugat Adhikari
    Surendra Sapkota
    Suraj Shrestha
    Kshitiz Karki
    Anjan Shrestha
    Orphanet Journal of Rare Diseases, 18
  • [24] ASSESSMENT OF FERRIC OVERLOAD IN PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA TREATED WITH ECULIZUMAB
    Eduardo Jose, Salido Fierrez
    Piqueras Mercedes, Berenguer
    Perianes Valentin, Cabanas
    Raul, Perez-Lopez
    Faustino, Garcia-Candel
    Juan Jose, Cerezo Manchado
    Ana Maria, Garcia-Hernandez
    Amor Antonia, Melero
    Arnao Maria, Moya
    Marin Amelia, Martinez
    Poveda Elena, Fernandez
    Almenzar Begona, Navarro
    Jose Maria, Moraleda Jimenez
    HAEMATOLOGICA, 2016, 101 : 263 - 264
  • [25] Fibrinogen and Clot Structure Is Affected By Eculizumab in Patients with Paroxysmal Nocturnal Haemoglobinuria
    Macrae, Fraser
    Bowman, Polly
    Linton, Emma
    Peacock-Young, Barnaby
    Clarke, Deborah
    Newton, Darren J.
    McKinley, Claire E.
    Riley, Kathryn
    Copeland, Nicola
    Arnold, Louise
    Griffin, Morag
    Munir, Talha
    Hillmen, Peter
    Richards, Stephen John
    Ariens, Robert
    Hill, Anita
    BLOOD, 2017, 130
  • [26] Eculizumab A Review of its Use in Paroxysmal Nocturnal Haemoglobinuria
    McKeage, Kate
    DRUGS, 2011, 71 (17) : 2327 - 2345
  • [27] Serologic Response to Meningococcal Vaccination in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) for the Chronic Treatment with the Terminal Complement Inhibitor Eculizumab
    Roeth, Alexander
    Alashkar, Ferras
    Herich-Terhuerne, Doerte
    Elias, Johannes
    Vogel, Ulrich
    Duehrsen, Ulrich
    BLOOD, 2014, 124 (21)
  • [28] Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab
    Alashkar, Ferras
    Vance, Colin
    Herich-Terhuerne, Doerte
    Preising, Nicole
    Duehrsen, Ulrich
    Roeth, Alexander
    ANNALS OF HEMATOLOGY, 2017, 96 (04) : 589 - 596
  • [29] Serologic response to meningococcal vaccination in patients with paroxysmal nocturnal hemoglobinuria (PNH) chronically treated with the terminal complement inhibitor eculizumab
    Ferras Alashkar
    Colin Vance
    Dörte Herich-Terhürne
    Nicole Preising
    Ulrich Dührsen
    Alexander Röth
    Annals of Hematology, 2017, 96 : 589 - 596
  • [30] Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
    Rother, Russell P.
    Rollins, Scott A.
    Mojcik, Christopher F.
    Brodsky, Robert A.
    Bell, Leonard
    NATURE BIOTECHNOLOGY, 2007, 25 (11) : 1256 - 1264
12345